



Contact: Michael Vitek, PhD, CEO
Location: Research Triangle Park, NC, USA
Email: mikevitek@cognosci.com
Tel: 919.765.0028 ext. 1
Website: www.cognosci.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Overview

Industry Sector: Pharmaceutical

Company Overview: Cognosci Inc. was founded in May 2000 to develop neuroprotective and neuroregenerative therapies for major neurological disorders such as Multiple Sclerosis (MS), Alzheimer's Disease (AD), and Traumatic Brain Injuries (TBI). Each of these disorders has a pharmacogenomic linkage to the apolipoprotein E (APOE) protein and people with the ε4 allele typically suffer worse outcomes. Based on these findings, scientists from Duke University created novel APOE-based compounds that have potent anti-inflammatory and neuroprotective activities. Cognosci has purchased all rights to these compounds from Duke and has performed extensive lead optimization and preclinical development programs and is now poised to enter human clinical trials. Optimized compounds have been shown to be efficacious in predictive animal models of MS, AD, and TBI. Cognosci is currently seeking \$12-15 million in Series A venture funding in order to complete final preclinical toxicology studies, Phase I clinical trials, and to initiate Phase II proof of principle trials.

Target Market(s): Multiple Sclerosis patients worldwide.

Key Value Drivers

Technology: COG compounds are a series of apoE-mimetic peptides that have demonstrated anti-inflammatory and neuroprotective effects on various in vitro and in vivo models of multiple Central Nervous System (CNS) diseases. For the case of Multiple Sclerosis, our lead compound COG112 only can suppress neuroinflammation, but also can help to repair the damaged myelin sheath and broken axons, indicating a neuroreparative activity. Therefore, COG compounds possess three beneficial activities: anti-inflammation, remyelination and neuroregeneration.

Competitive Advantage: 1) First-in-class neurorestorative therapy for most brain injury indications; 2) 3-in-1 combined beneficial properties; 3) small neuropeptides that can cross the blood-brain barrier; 4) Strong IP position; 5) First remyelination therapy for MS that can meet critically unmet need for such a therapy; 6) vast potential market: for MS, >\$15 billion in 2014.

Plan & Strategy: seeking venture capital investment and/or a strategic partner

Exit Plan: Acquisition or merger.

Management

Leadership:

Michael Vitek, PhD, Founder, President and CEO
 Dale Christensen, PhD, Vice President of Business Development
 Feng-Qiao Li, PhD, Vice President of Research

Scientific Advisory Board:

Bruce Trapp, Ph.D.: Scientific Consultant for MS program
 Chairman of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic Foundation; Distinguished Professor of Neurosciences at Case Western Reserve University
Paul O'Connor, M.D.- Multiple Sclerosis Clinical Trial Design and Performance
 Dr. O'Connor is a neurologist who heads up the MS Clinic at St. Michael's Hospital as well as the MS Program in the Division of Neurology at the University of Toronto. Dr. O'Connor has a vast experience with the clinical aspects of MS and directs one of the largest and most clinically active MS centers in the world.

Product Pipeline

